Regulus Therapeutics
RGLS
#6949
Rank
A$0.85 B
Marketcap
A$12.35
Share price
0.00%
Change (1 day)
424.12%
Change (1 year)

Regulus Therapeutics (RGLS) - Total liabilities

Total liabilities on the balance sheet as of March 2025 : A$8.77 Million

According to Regulus Therapeutics's latest financial reports the company's total liabilities are A$8.77 Million. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Regulus Therapeutics - Total liabilities on balance sheet (from 2011 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31A$12.49 M-10.97%
2023-12-31A$14.03 M-28.85%
2022-12-31A$19.72 M5.98%
2021-12-31A$18.61 M23.63%
2020-12-31A$15.05 M-52.22%
2019-12-31A$31.51 M-34.27%
2018-12-31A$47.95 M-12.11%
2017-12-31A$54.55 M-11.8%
2016-12-31A$61.85 M164.98%
2015-12-31A$23.34 M-51.59%
2014-12-31A$48.22 M45.28%
2013-12-31A$33.19 M-16.73%
2012-12-31A$39.86 M-51.56%
2011-12-31A$82.28 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
GlaxoSmithKline
GSK
A$92.76 B 1,056,892.07%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sanofi
SNY
A$99.94 B 1,138,690.96%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
A$16.65 B 189,620.59%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
A$103.66 B 1,181,083.17%๐Ÿ‡ฌ๐Ÿ‡ง UK
Alnylam Pharmaceuticals
ALNY
A$6.98 B 79,544.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
A$0.12 B 1,321.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$118.50 B 1,350,175.96%๐Ÿ‡บ๐Ÿ‡ธ USA